Targeting Type 1 Diabetes Before and at the Clinical Onset of Disease

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 6, Iss. 1, 2006-03 ,pp. : 103-124

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes

By Bak Ann Mosegaard   Egefjord Lærke   Gejl Michael   Steffensen Charlotte   Stecher Chalotte Willemann   Smidt Kamille   Brock Birgitte   Rungby Jørgen  

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 10, 2011-10 ,pp. : 1153-1162

Informa Healthcare

Access to resources Recommend Favorite

Incretin-Targeting Technologies for Type 2 Diabetes: Dipeptidyl Peptidase IV Inhibitors and Glucagon-Like Peptide-1 Analogs

By Adis International Limited  

Pharmaceutical & Diagnostic Innovation, Vol. 4, Iss. 7, 2006-07 ,pp. : 3-7

Adis International

Access to resources Recommend Favorite

Can targeting SIRT-1 to treat type 2 diabetes be a good strategy? A review

By Pulla Venkat Koushik   Battu Madhu Babu   Alvala Mallika   Sriram Dharmarajan   Yogeeswari Perumal  

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 8, 2012-08 ,pp. : 819-832

Informa Healthcare

Access to resources Recommend Favorite

Targeting SUMOylation Cascade for Diabetes Management

By  

Current Drug Targets, Vol. 15, Iss. 12, 2014-11 ,pp. : 1094-1106

Bentham Science Publishers

Access to resources Recommend Favorite